Joanna Horobin

Joanna Horobin, MB, ChB, is the former Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim). Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.